Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing ...

本次美国天境宣布暂停对CD73单抗Uliledlimab开发的原因是——以便公司能将资源集中在推进核心项目givastomig的开发上。因此，对Uliledlimab的进一步临床投资将被搁置。并未披露是否与Uliledlimab的本身有关。

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

TJ-L1H3 a B7-H3 antibody, TJ-L1D5 a CD73 antibody, and TJ-L1C4 a CD47 antibody—all of which have been shown to act synergistically with the PD-L1 backbone in preclinical assays and animal cancer ...

Uliledlimab (TJ004309) is an antibody designed to target CD73, the rate-limiting enzyme critical for adenosine-driven immunosuppression in the tumor microenvironment. I-Mab owns worldwide rights to ...

I-Mab shifts focus to givastomig, a bispecific antibody for CLDN18.2-positive tumors, following positive early data and ...

I-Mab, a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment ...

AZ is still testing the drug in the phase 3 PACIFIC-9 trial, looking at its PD-L1 checkpoint inhibitor Imfinzi (durvalumab) plus either monalizumab or anti-CD73 monoclonal antibody oleclumab in ...

The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.